Articles related to ANTIHYPERTENSIVES

In two randomized phase‑3 trials, a single‑pill triple low‑dose antihypertensive combination achieved blood pressure reductions comparable to amlodipine and superior to losartan monotherapy over 8 weeks.

Baxdrostat significantly reduced seated systolic blood pressure compared to placebo in 796 patients, with placebo-adjusted reductions of 9.8 mmHg and 8.7 mmHg at the 2 mg and 1 mg doses respectively, without impacting cortisol levels.

The researchers discovered that findings among older adults reinforced the guideline shift toward personalized, risk-based care.

The FDA says on its website that it has been investigating drugs for nitrosamines in some types of medications, noting they’re common in water and foods. But the agency noted that such impurities have been linked to an increase in cancer in individuals who are exposed to elevated levels and over long periods of time.

Triple therapy was linked with slower decline of overall cognition, particularly in semantic and working memory, and showed lower odds of atherosclerosis, reduced AD pathology, and fewer protein buildups.

Bedtime antihypertensive dosing achieved superior nocturnal blood pressure control with 79% versus 69.8% nighttime systolic control rates and required fewer dose escalations than morning administration.